Onartuzumab MetMAb|cas:1133766-06-9|西域试剂

Onartuzumab MetMAb,99.62%

产品编号：Bellancom-P99250| CAS NO：1133766-06-9

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99250		￥5400.00	杭州北京（现货）
Bellancom-P99250		￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Onartuzumab MetMAb

产品介绍

Onartuzumab (MetMAb) 是一种人源化亲和成熟的单价单克隆抗体，抑制受体酪氨酸激酶 MET。Onartuzumab 可有效抑制 HGF 结合、受体磷酸化和信号转导。Onartuzumab 具有抗体样药代动力学和抗肿瘤活性。

生物活性

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity.

体外研究

Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET.
Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells
Dosage:	30 mg/kg
Administration:	IP, twice a week for 2 mouth
Result:	Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.

Animal Model:	U-87 MG tumor-bearing mice
Dosage:	30 mg/kg
Administration:	IP, once
Result:	Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).

体内研究

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells
Dosage:	30 mg/kg
Administration:	IP, twice a week for 2 mouth
Result:	Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.

Animal Model:	U-87 MG tumor-bearing mice
Dosage:	30 mg/kg
Administration:	IP, once
Result:	Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).